MOUNTAIN VIEW, Calif., March 23, 2020 /PRNewswire/ -- AliveCor, the leader in artificial intelligence (AI)-based, personal ECG technology, and provider of enterprise cardiology solutions, today ...

AliveCor has received clearance for its portable ECG to calculate a patient’s QTc Interval. This FDA action follows the enforcement policy for non-invasive devices issued by the agency in March 2020 ...

Starting today, medical professionals can use KardiaMobile 6L for patients, both in-hospital and at home, to evaluate QTc. ECG data will flow directly from AliveCor's clinician platform to a ...

Please provide your email address to receive an email when new articles are posted on . AliveCor announced it received FDA 510(k) clearance for its mobile, handheld ECG device for the calculation of a ...

As more consumer-facing devices add features to measure the heart’s electrical activity, companies are looking for new ways to turn this data into valuable health information. AliveCor, a startup that ...

men, trans people having hormone treatment, and intersex people who have QTc longer than 440 milliseconds people who have a follow-up ECG with more than a 50‑millisecond increase in QTc. For trans ...

AliveCor is also offering a service called InstantQT™ to assist in measuring QT intervals through an FDA-cleared, ECG processing software. The Food and Drug Administration (FDA) has cleared the ...

Mobile electrocardiography (mECG) devices can go places a standard 12-lead electrocardiography system can't, with fewer technicians in tow, but it doesn't have the same functionality — their most ...

the effectiveness (diagnostic accuracy) of using KardiaMobile 6L to measure QT interval in adults having or about to have antipsychotic medications and the effect of the corrected QT interval (QTc) ...